Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Monoclonal Antibody a Promising Treatment for Depression



Akhondzadeh S1
Authors

Source: Avicenna Journal of Medical Biotechnology Published:2019

Abstract

[No abstract available]
Related Docs
View other Related Docs
1. Efficacy and Safety of Celecoxib for Treatment of Mild to Moderate Postpartum Depression: A Randomized, Double-Blind, Placebo-Controlled Trial, Archives of Gynecology and Obstetrics (2024)
2. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)
3. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (20)
Somaye Arabzadeh (3)
Other Related Docs
4. A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents With Acute Bipolar Mania, Journal of Child and Adolescent Psychopharmacology (2017)
5. Comparison of Saffron Versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial, Pharmacopsychiatry (2017)
6. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
7. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)
8. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)
9. Therapeutic Effects of Minocycline on Mild-To-Moderate Depression in Hiv Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, International Clinical Psychopharmacology (2016)
10. Celecoxib in Treatment of Postpartum Depression: A Case Report, Archives of Iranian Medicine (2023)
11. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study, Pharmacopsychiatry (2016)
12. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
13. L-Carnosine As an Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Psychiatry Research (2018)
14. Efficacy and Safety of Celecoxib Monotherapy for Treatment of Moderate Depressive Symptoms Following Covid-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2023)
15. Pioglitazone Adjunctive Therapy for Depressive Episode of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Depression and Anxiety (2015)
16. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)
17. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)
18. L-Carnosine As Adjunctive Therapy in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Child and Adolescent Psychopharmacology (2018)
19. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Neuropharmacology (2017)
20. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)